The University of Kent’s School of Biosciences and the Institute of Medical Virology at Goethe-University, Frankfurt am Main, have identified a protein that may critically contribute to severe forms of COVID-19.
Researchers at the University of Liverpool have shown how SARS-CoV-2 viral proteases attack the host cell, and how this can be targeted to stop virus replication in cell culture using existing drugs.
A first-of-its-kind study of young adults with positive COVID-19 tests from more than 4 weeks ago found that those who were still symptomatic (i.e., long-haulers) had impaired blood vessel function in their limbs, but not brains. Asymptotic participants had blood vessel function similar to controls.
Researchers at McMaster University have developed a sophisticated new tool that could help provide early warning of rare and unknown viruses in the environment and identify potentially deadly bacterial pathogens which cause sepsis, among other uses.
The most comprehensive analysis of the 3D structure of SARS-CoV-2 to date has revealed new insight on how the virus infects human cells and replicates.
A research team has identified a potential cause of long-lasting symptoms experienced by COVID-19 patients, often referred to as long-haulers. The findings were published in the journal, The Public Library of Science ONE (PLOS ONE).
The presence of special immune system defense molecules, called autoimmune antibodies, has been strongly tied to how poorly people fare when hospitalized with COVID-19, a new study shows.
Researchers found that breastfeeding mothers who received either the Pfizer-BioNTech or Moderna vaccination reported the same local or systemic symptoms as what has been previously reported in non-breastfeeding women, with no serious side effects in the breastfed infants.
Argonne, industry and academia collaborate to bring innovative AI and simulation tools to the COVID-19 battlefront.
News stories in this issue
After more than 50 days on advanced life support, a multi-disciplinary team at UC San Diego Health helps a patient who contracted COVID-19 become a candidate for a successful double lung transplant. The transplant surgery was the first in the region performed on a COVID-19 patient.
Researchers at Washington University School of Medicine in St. Louis have identified an antibody that is highly protective against a broad range of viral variants.
Vaccination against SARS-CoV-2 substantially lowers the risks of “breakthrough” infections and death due to COVID-19 in adult organ transplant recipients, according to a pair of research letters in Transplantation, the official Journal of The Transplantation Society and the International Liver Transplantation Society. The journal is published in the Lippincott portfolio by Wolters Kluwer.
NEWS STORIES IN THIS ISSUE:
– COVID-19 NEWS: Johns Hopkins Medicine Study Shows Vaccine Likely Protects People with HIV
– Johns Hopkins Medicine Documents Stroke Risk in Cardiac Assist Device
– CBD Products May Help People with Epilepsy Better Tolerate Anti-Seizure Medications
Part of UC San Diego’s Return to Learn program, wastewater screening helped prevent outbreaks by detecting 85 percent of cases early, allowing for timely testing, contact tracing and isolation.
With recent statewide vaccination mandates, members of the public may have questions or concerns about the safety and effectiveness of COVID-19 vaccination, especially in pregnant mothers. Cynthia Gyamfi-Bannerman, MD, professor and chair of Obstetrics, Gynecology and Reproductive Sciences at UC…
A licensed drug normally used to treat abnormal levels of fatty substances in the blood could reduce infection caused by the SARS-CoV-2 virus by up to 70 per cent, reveals a study in the laboratory by an international collaboration of researchers.
New York, NY – Researchers from the Icahn School of Medicine at Mount Sinai have found that most COVID-19 patients have persistent antibodies to the SARS-CoV-2 virus at levels that are correlated with neutralization of the virus more than…
The levels of IgG antibodies against SARS-CoV-2 Spike protein remain stable, or even increase, seven months after infection, according to a follow-up study in a cohort of healthcare workers coordinated by the Barcelona Institute for Global Health (ISGlobal), an institution supported by “la Caixa” Foundation, in collaboration with the Hospital Clinic of Barcelona.
UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.
How long do coronaviruses remain infectious on banknotes and coins? Is it possible to become infected through contact with cash?
Two different strategies to discover and perfect pharmaceuticals active against the COVID-19 virus have attracted a half million dollars in research funding to support five institutions, including the Baudry Lab at The University of Alabama in Huntsville (UAH).
Göttingen researchers have developed mini-antibodies that efficiently block the coronavirus SARS-CoV-2 and its dangerous new variants.
Researchers at Stanford and Berkeley Lab’s Molecular Foundry have developed virus-killing molecules called peptoids. The technology could make possible an emerging category of antiviral drugs that could treat everything from herpes and COVID-19 to the common cold.
Scientists have developed a rapid, highly accurate test to detect antibodies against the spike protein of SARS-CoV-2 in human serum, opening a new avenue for understanding the full extent of the pandemic and evaluating the effectiveness of vaccines.
Two teams of researchers using the Advanced Photon Source identified existing drugs — one used to treat cancer, the other an anti-seizure medication — that may work as treatments for COVID-19.
Os pesquisadores e colaboradores da Mayo Clinic usaram a simulação em computadores e inteligência artificial (AI) para fazer a triagem virtual de 30 milhões de possíveis medicamentos que podem bloquear o SARS-CoV-2, o vírus que causa a COVID-19.
Researchers at Johns Hopkins Medicine have shown that a type of echocardiogram, a common test to evaluate whether a person’s heart is pumping properly, may be useful in predicting which patients with COVID-19 are most at risk of developing atrial fibrillation — an irregular heartbeat that can increase a person’s risk for heart failure and stroke, among other heart issues. The new findings, published online May 30 in the Journal of the American Society of Echocardiography, also suggest that patients with COVID-19 who go on to develop atrial fibrillation more commonly have elevated levels of heart-related proteins called troponin and NT-proBNP in blood test samples.
Researchers at Texas Biomedical Research Institute (Texas Biomed) have narrowed down the proteins enabling SARS-CoV-2 to cause disease. Using advanced genetic engineering techniques developed at Texas Biomed, they systematically deleted the genetic code for five of the virus’s accessory proteins, one at a time, to see how each one affected the virus’s ability to spread and cause illness. The research was published online this month in the Journal of Virology.
UC San Diego Health is now offering a verifiable digital vaccine record to its patients who have or will receive a COVID-19 vaccine. These secure online records, otherwise known as a SMART health card, can be accessed directly from the MyUCSDChart patient portal.
A new study confirms the low likelihood that coronavirus contamination on hospital surfaces is infectious. The study is the original report on recovering near-complete SARS-CoV-2 genome sequences directly from surface swabs.
The virus that causes COVID-19 normally gets inside cells by attaching to a protein called ACE2. Researchers at Washington University School of Medicine in St. Louis have found that a single mutation confers the ability to enter cells through another route, which may threaten the effectiveness of COVID-19 vaccines and therapeutics designed to block the standard route of entry.
A new study in ACS Nano supports increasing evidence that people who had COVID-19 need only one vaccine dose, and that boosters could be necessary for everyone in the future.
Scientists are pursuing a new strategy in the protracted fight against the SARS-CoV-2 virus by engineering nanobodies that can neutralize virus variants in two different ways.
A study from Washington University School of Medicine in St. Louis suggests that many, but not all, COVID-19 therapies made from combinations of two antibodies are effective against a wide range of virus variants, and that combination therapies appear to prevent the emergence of drug resistance.
This study investigates how the nucleocapsid protein, or N protein, of the SARS-CoV-2 virus packages the viral genome.
The number of COVID-19 variants is growing rapidly, so much that the scale and scope of mutation may pose a threat to the continuing successful use of the current vaccines and therapies. The findings, by an international team that includes University of California researchers, are being published in the June edition of the peer-reviewed journal EMBO Molecular Medicine. The pace of variation of the SARS-CoV-2 virus strains makes plain the threat that rapidly evolving new strains might give rise to escape variants, capable of limiting the efficacy of vaccines, therapies, and diagnostic tests.
Artificial intelligence (AI) may offer a way to accurately determine that a person is not infected with COVID-19. An international retrospective study finds that infection with SARS-CoV-2, the virus that causes COVID-19, creates subtle electrical changes in the heart. An AI-enhanced EKG can detect these changes and potentially be used as a rapid, reliable COVID-19 screening test to rule out COVID-19 infection.
In a study published today in the Annals of Internal Medicine, Johns Hopkins Medicine researchers say they believe that, for the first time, there is evidence to show that three doses of vaccine increase antibody levels against SARS-CoV-2 — the virus that causes COVID 19 — more than the standard two-dose regimen for people who have received solid organ transplants.
UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.
UC San Diego School of Medicine researchers discovered that SARS-CoV-2, or at least its genetic signature, abounds on hospital surfaces, often co-locating with one particular type of bacteria.
NEWS STORIES IN THIS ISSUE:
-Physician and Musician: Johns Hopkins Doctor Brings Passion for Music to Medicine During Pandemic
-Rapid, At-Home Blood Test Could Confirm COVID-19 Vaccination in Minutes
-What to Expect and Prepare for As You Return to Regular Health Care Appointments
-Study Suggests Sudden Hearing Loss Not Associated with COVID-19 Vaccination
-Vaccination May Not Rid COVID-19 Risk for Those with Rheumatic, Musculoskeletal Diseases
A coalition of six U.S. subsidiary companies have sponsored a COVID-19 mobile clinic to vaccinate 10,000 maquiladora workers employed in Baja California, Mexico. UC San Diego Health is vaccinating about 1,500 workers daily.
Within the next decade, the novel coronavirus responsible for COVID-19 could become little more than a nuisance, causing no more than common cold-like coughs and sniffles. That possible future is predicted by mathematical models that incorporate lessons learned from the current pandemic on how our body’s immunity changes over time. Scientists at the University of Utah carried out the research, now published in the journal Viruses.
Study Has Implications for Preventive Measures to Slow Spread of Virus
A new study’s findings dispel the misconception that patients and providers are at high risk of catching COVID-19 at the dentist’s office.
According to The New York Times, the prospects for reaching “herd immunity” in the fight against COVID-19 are increasingly dim. Subsequently, the virus “will most likely become a manageable threat that will continue to circulate in the United States for…
In a study published today in the Journal of the American Medical Association (JAMA), Johns Hopkins Medicine researchers show that although two doses of a vaccine against SARS-CoV-2 — the virus that causes COVID 19 — confers some protection for people who have received solid organ transplants, it’s still not enough to enable them to dispense with masks, physical distancing and other safety measures.
New Brunswick, N.J. (April 30, 2021) – Rutgers University–New Brunswick engineering professors Edward P. DeMauro, German Drazer, Hao Lin and Mehdi Javanmard are available for interviews on their work to develop a new type of fast-acting COVID-19 sensor that detects the presence…